J.W. Cole Advisors Inc. Decreases Stake in TransMedics Group, Inc. (NASDAQ:TMDX)

J.W. Cole Advisors Inc. cut its holdings in TransMedics Group, Inc. (NASDAQ:TMDX) by 61.6% during the fourth quarter, Holdings Channel reports. The institutional investor owned 6,526 shares of the company’s stock after selling 10,449 shares during the quarter. J.W. Cole Advisors Inc.’s holdings in TransMedics Group were worth $515,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently modified their holdings of the business. Cutler Group LLC CA boosted its position in TransMedics Group by 600.0% during the third quarter. Cutler Group LLC CA now owns 700 shares of the company’s stock worth $38,000 after purchasing an additional 600 shares in the last quarter. Global Retirement Partners LLC purchased a new stake in shares of TransMedics Group in the third quarter valued at $38,000. RiverPark Advisors LLC purchased a new stake in shares of TransMedics Group in the third quarter valued at $60,000. Van ECK Associates Corp lifted its position in shares of TransMedics Group by 39.0% in the third quarter. Van ECK Associates Corp now owns 2,127 shares of the company’s stock valued at $116,000 after acquiring an additional 597 shares in the last quarter. Finally, Yarbrough Capital LLC purchased a new stake in shares of TransMedics Group in the fourth quarter valued at $201,000. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other TransMedics Group news, Director Edward M. Basile sold 7,157 shares of the company’s stock in a transaction dated Tuesday, February 6th. The stock was sold at an average price of $86.38, for a total transaction of $618,221.66. Following the completion of the sale, the director now directly owns 8,350 shares in the company, valued at $721,273. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other TransMedics Group news, Director Edward M. Basile sold 7,157 shares of the company’s stock in a transaction dated Tuesday, February 6th. The stock was sold at an average price of $86.38, for a total transaction of $618,221.66. Following the completion of the sale, the director now directly owns 8,350 shares in the company, valued at $721,273. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Stephen Gordon sold 15,000 shares of the company’s stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $74.01, for a total value of $1,110,150.00. Following the completion of the sale, the chief financial officer now directly owns 23,299 shares of the company’s stock, valued at approximately $1,724,358.99. The disclosure for this sale can be found here. Insiders sold 117,078 shares of company stock worth $9,972,971 over the last three months. 6.70% of the stock is owned by insiders.

TransMedics Group Stock Up 4.7 %

TransMedics Group stock opened at $90.60 on Wednesday. The stock has a fifty day moving average price of $82.95 and a 200 day moving average price of $74.01. TransMedics Group, Inc. has a 52 week low of $36.42 and a 52 week high of $99.63. The company has a current ratio of 9.30, a quick ratio of 8.49 and a debt-to-equity ratio of 3.69.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings results on Monday, February 26th. The company reported $0.12 EPS for the quarter, topping the consensus estimate of ($0.10) by $0.22. The company had revenue of $81.20 million during the quarter, compared to analyst estimates of $68.49 million. TransMedics Group had a negative return on equity of 2.35% and a negative net margin of 10.36%. The firm’s revenue was up 158.6% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.21) earnings per share. As a group, analysts expect that TransMedics Group, Inc. will post -0.14 earnings per share for the current year.

Analysts Set New Price Targets

TMDX has been the topic of several recent research reports. Oppenheimer upped their price objective on TransMedics Group from $92.00 to $105.00 and gave the company an “outperform” rating in a research report on Tuesday, February 27th. JPMorgan Chase & Co. upped their price objective on TransMedics Group from $87.00 to $105.00 and gave the company an “overweight” rating in a research report on Tuesday, February 27th. Piper Sandler initiated coverage on TransMedics Group in a research report on Thursday, March 28th. They issued an “overweight” rating and a $95.00 price objective on the stock. Finally, Morgan Stanley upped their price objective on TransMedics Group from $75.00 to $95.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 28th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $102.00.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.